Kala Pharmaceuticals (NASDAQ:KALA) Posts Earnings Results, Misses Expectations By $0.01 EPS

Share on StockTwits

Kala Pharmaceuticals (NASDAQ:KALA) announced its quarterly earnings results on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01), Fidelity Earnings reports. The firm had revenue of $1.45 million for the quarter, compared to analyst estimates of $3.56 million.

Kala Pharmaceuticals stock traded up $0.40 during trading on Friday, hitting $4.11. The company had a trading volume of 374,000 shares, compared to its average volume of 249,192. The company has a current ratio of 7.50, a quick ratio of 7.04 and a debt-to-equity ratio of 1.16. The stock has a market cap of $126.17 million, a price-to-earnings ratio of -1.66 and a beta of 2.13. Kala Pharmaceuticals has a 1-year low of $3.24 and a 1-year high of $9.25. The company’s 50 day simple moving average is $3.84 and its 200-day simple moving average is $5.11.

Several analysts recently weighed in on the stock. ValuEngine upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Wednesday. HC Wainwright dropped their target price on shares of Kala Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their target price on shares of Kala Pharmaceuticals from $22.00 to $14.00 and set an “overweight” rating for the company in a report on Friday. Finally, Wedbush reiterated an “outperform” rating and issued a $51.00 target price on shares of Kala Pharmaceuticals in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Kala Pharmaceuticals has a consensus rating of “Buy” and an average price target of $17.54.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

See Also: Index Funds

Earnings History for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.